GSK has announced the launch of two oncology treatments, Jemperli (dostarlimab) and Zejula (niraparib), in India. Jemperli has received approval for use as a second-line treatment for patients with advanced endometrial cancer, while Zejula has been approved as a first-line maintenance monotherapy for individuals with advanced ovarian cancer.

GSK 宣布在印度推出两种肿瘤治疗药物 Jemperli（dostarlimab）和 Zejula（niraparib）。Jemperli 已获准用于晚期子宫内膜癌患者的二线治疗，而 Zejula 则被批准作为晚期卵巢癌患者的一线维持单药治疗。

This development marks an expansion of GSK’s oncology portfolio in the Indian market..

这一进展标志着GSK在印度市场上的肿瘤学产品组合的扩展。

Jemperli is specifically indicated for patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) advanced endometrial cancer that has progressed after prior treatment. Meanwhile, Zejula is designed to be used as a maintenance therapy following platinum-based chemotherapy in adult patients with advanced ovarian cancer, regardless of their biomarker status.

Jemperli 专门用于错配修复缺陷 (dMMR) 或高微卫星不稳定性 (MSI-H) 的晚期子宫内膜癌患者，这些患者在先前治疗后病情已恶化。同时，Zejula 旨在作为维持治疗，用于接受含铂化疗后的成年晚期卵巢癌患者，无论其生物标志物状态如何。

Both drugs aim to address critical unmet needs in the treatment landscape for these cancers..

这两种药物旨在解决这些癌症治疗领域中未满足的关键需求。